Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that its Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website.
The company, which operates under the commercial name Helus Pharma and was founded in 2019, is dedicated to developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These investigational therapies aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma’s most advanced candidate, HLP003, is a proprietary NSA currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. It has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, which may expedite its development and review. The company is also developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma maintains an extensive research portfolio of investigational NSAs.
The fireside chat at the Jefferies conference provides an opportunity for the company to communicate its progress and strategy to investors and industry leaders. For business and technology leaders, the implications are significant: Helus Pharma’s approach targets the large and growing market for mental health treatments, where current options often have limited efficacy or significant side effects. If successful, HLP003 and HLP004 could offer new, potentially more durable solutions for millions of patients worldwide.
The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company’s website at www.helus.com. The full press release is available at https://ibn.fm/1QdP7, and the latest news and updates relating to HELP can be found in the company’s newsroom at https://ibn.fm/HELP.
This announcement underscores the growing interest in psychedelic-inspired therapies and the potential for novel mechanisms to transform mental health care. As the company advances its clinical programs, the outcomes of these trials could have a profound impact on the treatment landscape for depression and anxiety disorders.
